Literature DB >> 24421459

Drug monographs: bosutinib and regorafenib.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421459      PMCID： PMC3839511          DOI： 10.1310/hpj4803-190

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  10 in total

1.  A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Authors:  Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

2.  Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Authors:  M Campone; I Bondarenko; S Brincat; Y Hotko; P N Munster; E Chmielowska; P Fumoleau; R Ward; N Bardy-Bouxin; E Leip; K Turnbull; C Zacharchuk; R J Epstein
Journal:  Ann Oncol       Date:  2011-06-23       Impact factor: 32.976

3.  A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.

Authors:  Richat Abbas; Bruce A Hug; Cathie Leister; Daryl Sonnichsen
Journal:  Int J Cancer       Date:  2011-12-14       Impact factor: 7.396

4.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Authors:  Jorge E Cortes; Hagop M Kantarjian; Tim H Brümmendorf; Dong-Wook Kim; Anna G Turkina; Zhi-Xiang Shen; Ricardo Pasquini; H Jean Khoury; Steven Arkin; Angela Volkert; Nadine Besson; Richat Abbas; Junyuan Wang; Eric Leip; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

5.  Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Authors:  Suzanne George; Qian Wang; Michael C Heinrich; Christopher L Corless; Meijun Zhu; James E Butrynski; Jeffrey A Morgan; Andrew J Wagner; Edwin Choy; William D Tap; Jeffrey T Yap; Annick D Van den Abbeele; Judith B Manola; Sarah M Solomon; Jonathan A Fletcher; Margaret von Mehren; George D Demetri
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

6.  A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Authors:  Richat Abbas; Bruce A Hug; Cathie Leister; Myriam El Gaaloul; Stephan Chalon; Daryl Sonnichsen
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-21       Impact factor: 3.333

7.  Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Authors:  Adil I Daud; Smitha S Krishnamurthi; Mansoor N Saleh; Barbara J Gitlitz; Mitesh J Borad; Philip J Gold; Elena G Chiorean; Gregory M Springett; Richat Abbas; Shefali Agarwal; Nathalie Bardy-Bouxin; Poe-Hirr Hsyu; Eric Leip; Kathleen Turnbull; Charles Zacharchuk; Wells A Messersmith
Journal:  Clin Cancer Res       Date:  2011-12-16       Impact factor: 12.531

8.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Hagop M Kantarjian; Tim H Brümmendorf; Irina Dyagil; Laimonas Griskevicius; Hemant Malhotra; Christine Powell; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

9.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

10.  Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Authors:  D Strumberg; M E Scheulen; B Schultheis; H Richly; A Frost; M Büchert; O Christensen; M Jeffers; R Heinig; O Boix; K Mross
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640
  10 in total
  1 in total

Review 1.  Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.

Authors:  Sujan Ravi; Ashwani K Singal
Journal:  Core Evid       Date:  2014-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.